BioNTech (NASDAQ:BNTX) Price Target Raised to $121.00

BioNTech (NASDAQ:BNTX) had its price target raised by JPMorgan Chase & Co. from $116.00 to $121.00 in a report published on Monday,Benzinga reports. The firm currently has a neutral rating on the stock.

Several other brokerages also recently weighed in on BNTX. Morgan Stanley increased their price target on shares of BioNTech from $132.00 to $133.00 and gave the stock an “overweight” rating in a report on Thursday, July 10th. Truist Financial reiterated a “buy” rating and issued a $155.00 price target (up previously from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Leerink Partners set a $112.00 price objective on BioNTech in a research report on Monday, June 2nd. Wells Fargo & Company set a $150.00 price objective on BioNTech and gave the stock an “overweight” rating in a research report on Tuesday, August 5th. Finally, Bank of America upped their price objective on BioNTech from $126.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Eleven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $134.56.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $99.75 on Monday. BioNTech has a twelve month low of $81.20 and a twelve month high of $129.27. The company’s 50 day moving average is $106.60 and its 200 day moving average is $103.25. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. The company has a market cap of $23.98 billion, a PE ratio of -62.34 and a beta of 1.39.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The business had revenue of $306.46 million during the quarter, compared to analyst estimates of $161.26 million. During the same quarter last year, the company posted ($3.36) EPS. BioNTech’s quarterly revenue was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that BioNTech will post -3.88 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BNTX. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of BioNTech by 19.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 221,080 shares of the company’s stock valued at $25,192,000 after buying an additional 36,746 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of BioNTech during the 4th quarter valued at approximately $235,000. Jefferies Financial Group Inc. purchased a new position in shares of BioNTech during the 4th quarter valued at approximately $570,000. Probity Advisors Inc. lifted its position in shares of BioNTech by 8.5% during the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock valued at $224,000 after buying an additional 154 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in shares of BioNTech during the 4th quarter valued at approximately $238,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.